Call us Toll-Free
800-476-6070

Weitz & Luxenberg Facebook Weitz & Luxenberg Google Weitz & Luxenberg Twitter Weitz & Luxenberg LinkedIn
English En Français

FREE LEGAL REVIEW

First Name
Last Name
Home Phone
Work Phone
City and State
Email
Were you diagnosed with Asbestosis? Yes
Were you diagnosed with lung cancer? Yes
Were you diagnosed with Mesothelioma? yes
What is your date of diagnosis?
Additional Comments
Best time to call?

Clinical Trials for Mesothelioma Patients—A Study of Safety and Tolerability of Intravenous CRS-207: Exclusion Criteria

Here is some free information on mesothelioma research from mesothelioma lawyers. Learn about the exclusion criteria for a current clinical trial about the safety and tolerability of intravenous CRS-207 in patients with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only.

Exclusion Criteria:
1. History of infection with Listeria, prior vaccination with a listeria-based vaccine, or a positive fecal culture of Listeria at screening
2. Currently have or have history of certain study-specified heart, liver, kidney, lung, neurological, immune or other medical conditions
3. Allergy to penicillin or yeast or other component of the study drug product (e.g., glycerol)
4. Clinical metabolic or laboratory abnormalities defined as Grade 3 or 4 of the National Cancer Institute's (NCI's) Common Terminology Criteria for Adverse Events (CTCAE), version 3.0
5. Artificial (prosthetic) joint or other artificial implant or devices that cannot be easily removed
6. Known coagulation (blood clotting) disorder or recent thrombotic event
7. Certain types of blood transfusions within 14 days prior to receiving study drug or a condition requiring regular blood transfusions more than twice per month
8. Taking the following medications:
Anti-coagulation medications
Systemically active steroids for more than 2 days within 28 days prior to receiving study drug
More than 325 mg per day of aspirin
More than 2 g per day of acetaminophen
Systemic antibiotics within 14 days prior to receiving study drug
Another investigational product within 28 days prior to receiving study drug
9. Major surgery or significant traumatic injury (or unhealed surgical wounds) occurring within 28 days prior to receiving study drug, or planned surgery requiring general anesthesia
10. Infection with HIV, hepatitis B or C, or HTLV-1 (human t-lymphotropic virus type 1) at screening
11. Pregnant or lactating, or close contact with pregnant women or newborn babies
12. Conditions, including alcohol or drug dependence, intercurrent illness, or lack of sufficient peripheral venous access, that would affect the patient's ability to comply with study visits and procedures

If you have been diagnosed with an Asbestos illness like mesothelioma, lung cancer or asbestosis, complete the form on this page to get a FREE and prompt review of your case by a leading Asbestos attorney. Weitz & Luxenberg is a leading mesothelioma law firm with a substantial history of success in asbestos exposure cases.

Mesothelioma Mesothelioma Home Page
head Mesothelioma: An Overview
kleio The Clock Is Ticking
asbestos Our Toughest Cases
head Diagnosis
treatment Symptoms, Stages, Treatment
kleio Latest News
New York Numbers
Asbestos
Real Stories


IN THIS SECTION
CRS-207 and mesothelioma
Mesothelioma: CRS-207 description
Mesothelioma : Inclusion criteria for CRS-207
Mesothelioma: Exclusion criteria for CRS
Mesothelioma: Contacts for CRS


RETURN BACK TO
Mesothelioma
Mesothelioma Treatments
Treatment
Clinical trials for mesothelioma

For legal help anywhere in the U.S. call:

1 - 800 - 476 - 6070

Prior results do not guarantee a similar outcome.

ATTORNEY ADVERTISING

Mesothelioma Lawyer

Asbestos Lawyer

Mesothelioma Attorney

Asbestos Attorney

Mesothelioma Treatment

see also:

Mesothelioma : Inclusion criteria for CRS-207 Patient inclusion criteria for CRS-207 study on mesothelioma
Read about patient inclusion criteria for CRS-207 test on mesothelioma

Mesothelioma: CRS-207 description Study description of intravenous CRS-207 on mesothelioma
Clinical study description of intravenous CRS-207 test on mesothelioma

Intravenous CRS-207 for mesothelioma Clinical trial of intravenous CRS-207 on patients with mesothelioma
Clinical study to test intravenous CRS-207 on mesothelioma